

Dear NICE,

Thanks for the opportunity to comment on this ACD. We have no issues with either the evaluation or the ACD. We believe that the future of this and other such agents lies in appropriate testing for mutations, in order to select those patients most likely to benefit.

[REDACTED]

On behalf of the British Thoracic Society Lung Cancer and Mesothelioma Specialist Advisory Group